Nepexto Market Report 2026

Nepexto Market Overview

• The Nepexto market growth in the historic period has been driven by expansion of biologic drug usage in autoimmune diseases, rising healthcare cost containment efforts • Market expansion is supported by increasing penetration of biosimilars in specialty care, growing payer support for biosimilar substitution • Growth Driver: Rising Prevalence Of Chronic Diseases To Drive Market Growth • Market Trend: Emergence Of Biosimilar Advancements In The Market • Europe was the largest region in 2025.

What Is Covered Under Nepexto Market?

Nepexto is a biosimilar medication designed to provide an alternative treatment option for patients with autoimmune diseases. It is developed to closely resemble the reference biologic regarding safety, efficacy, and quality. Nepexto is typically used to treat conditions such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, offering patients a cost-effective and accessible therapeutic option. The main indication types of nepexto are growth hormone deficiency, short stature due to idiopathic causes, turner syndrome, and prader-willi syndrome. Growth hormone deficiency (GHD) is a medical condition caused by inadequate production of growth hormone by the pituitary gland, leading to stunted growth in children and metabolic dysfunctions in adults. The formulations are injectable solutions and pre-filled syringes or pens and distribution channels include hospitals, specialty clinics, retail pharmacies, and online pharmacies. It is used by various end users patients such as adult patients and pediatric patients.

What Is The Nepexto Market Growth Forecast?

The growth in the forecast period can be attributed to increasing penetration of biosimilars in specialty care, growing payer support for biosimilar substitution, expansion of outpatient biologic treatment, rising demand for self-injectable therapies, increasing global regulatory alignment. Major trends in the forecast period include increasing adoption of biosimilar therapies, rising demand for cost-effective autoimmune treatments, growing physician confidence in biosimilars, expansion of injectable biologic delivery formats, enhanced focus on regulatory harmonization.

Global Nepexto Market Segmentation

1) By Indication: Growth Hormone Deficiency, Short Stature Due To Idiopathic Causes, Turner Syndrome, Prader-Willi Syndrome 2) By Formulation: Injectable Solution, Pre-Filled Syringes Or Pens 3) By Distribution Channel: Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies 4) By End User Patients: Adult Patients, Pediatric Patients

What Are The Drivers Of The Nepexto Market?

The rising prevalence of chronic diseases is expected to drive the growth of the nepexto market going forward. A chronic disease is a long-lasting condition that typically persists for over three months, often requiring ongoing medical attention or limiting daily activities. Chronic diseases are on the rise due to factors such as aging populations, unhealthy lifestyles, and improvements in medical care that allow people with acute conditions to survive longer, thus increasing the prevalence of long-term health issues. Nepexto is used in the treatment of chronic autoimmune diseases such as rheumatoid arthritis and psoriatic arthritis, offering a cost-effective and accessible alternative for long-term disease management. For instance, in November 2023, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, reported that noncommunicable diseases (NCDs) kill 41 million people each year, equivalent to 74% of all deaths globally. Each year, 17 million people die from an NCD before age 70; 86% of these premature deaths occur in low- and middle-income countries. Of all NCD deaths, 77% are in low- and middle-income countries. Cardiovascular diseases account for most NCD deaths, or 17.9 million people annually, followed by cancers (9.3 million), chronic respiratory diseases (4.1 million), and diabetes. These 4 groups of diseases account for over 80% of all premature NCD deaths. Therefore, the growing prevalence of chronic diseases will drive the nepexto industry. The rise in healthcare expenditure is expected to drive the growth of the nepexto market going forward. Healthcare expenditure is the total amount spent on healthcare goods and services, including personal health care, preventive services, and public health activities to improve health outcomes within a specific period. Healthcare expenditure is rising due to an aging population, chronic diseases, advanced medical technology, high drug prices, inefficient payment models, and increased demand for services. Nepexto leverages healthcare expenditure by providing a cost-effective treatment option for chronic autoimmune diseases, helping to manage resource allocation while ensuring patient access to advanced biologic therapies. For instance, in November 2025, according to a Organisation for Economic Co operation and Development, a France-based intergovernmental international organization, reported that in 2024, average health spending in OECD countries was estimated to stand at nearly USD 6 000 per capita. The United States was the highest spender. Therefore, the rise in healthcare expenditure drives the nepexto industry.

Key Players In The Global Nepexto Market

Major companies operating in the nepexto market are Lupin Limited

Global Nepexto Market Trends and Insights

Major companies operating in the Nepexto market are focusing on developing biosimilars, such as etanercept, to gain a competitive edge in the industry. Etanercept biosimilars are biological medications designed to replicate the original etanercept’s structure, function, and therapeutic effects, primarily used to treat autoimmune conditions. For instance, in May 2024, Lupin, an India-based pharmaceutical company, partnered with Sandoz, a Switzerland-based pharmaceutical company, to launch Rymti, an etanercept biosimilar, in Canada. Rymti is expected to enhance treatment options for patients with chronic inflammatory diseases and provide a cost-effective alternative to existing therapies, contributing to sustainable healthcare solutions.

Regional Insights

Europe was the largest region in the nepexto market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Nepexto Market?

The nepexto market consists of sales of biologics, biosimilars, and recombinant proteins. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Nepexto Market Report 2026?

The nepexto market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the nepexto industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.